PMV Pharmaceuticals, Inc. — Company profile
Healthcare · Biotechnology · United States
Last price 1.35 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 101.94M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Company profile
PMV Pharmaceuticals, Inc., a precision oncology company, engages in the discovery and development of small molecule therapies targeting p53 mutations and other p53-related cancers in the United States. It develops rezatapopt, a selective structural corrector of p53 Y220C mutations in Phase 2 clinical trials for tumor agnostic diseases. The company was formerly known as PJ Pharmaceuticals, Inc. and changed its name to PMV Pharmaceuticals, Inc. in July 2013. PMV Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Princeton, New Jersey.
Details
| Name | PMV Pharmaceuticals, Inc. |
| Sector | Healthcare |
| Industry | Biotechnology |
| Employees | 54 |
| Founded | 2013 |
| Ipo Date | 2020-09-25 |
| Ceo | David Mack |
| Country | United States |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| Ipo Price | 18.00 |
| Isin | US69353Y1038 |
| Cusip | 69353Y103 |
| Cik | 1699382 |
| Sic | 2834 |
| Stock Type | Common Stock |
Key executives
| Name | Title |
|---|---|
| Dr. David H. Mack Ph.D. | Co-Founder, Chief Executive Officer, President and Director |
| Dr. Arnold J. Levine Ph.D. | Co-Founder, Independent Director and Member of Scientific Advisory Board |
| Robert Ticktin J.D. | General Counsel, Chief Operating Officer and Company Secretary |
| Dr. Deepika Jalota Pharm.D. | Chief Development Officer |
| Michael Carulli | Chief Financial Officer and Principal Financial & Accounting Officer |
| Tim Smith M.B.A. | Senior Vice President and Head of Corporate Development and Investor Relations |
Contact
| Address | 400 Alexander Park Drive, Suite 301, Princeton, New Jersey 08540, United States |
| Phone | 609 642 6670 |
| Website | https://www.pmvpharma.com |